AXGN AxoGen
- 5.890
- +0.060+1.03%
AxoGen News
AxoGen, Inc. (NASDAQ:AXGN) Q1 2024 Earnings Call Transcript
Earnings Call Summary | AxoGen(AXGN.US) Q1 2024 Earnings Conference
The following is a summary of the AxoGen, Inc. (AXGN) Q1 2024 Earnings Call Transcript:Financial Performance:AxoGen reported a Q1 revenue increase of 12.9% to $41.4 million compared to last year.Gross
AxoGen First Quarter 2024 Earnings: Misses Expectations
Axogen Reiterates FY24 Outlook: Expects Revenues To Grow Between $177M-$181M Vs. $179.51M Estimate, Which Represents A Growth Rate Of Approximately 11%-14%
Axogen Reiterates FY24 Outlook: Expects Revenues To Grow Between $177M-$181M Vs. $179.51M Estimate, Which Represents A Growth Rate Of Approximately 11%-14%
Axogen Q1 2024 Adj EPS $(0.06) Beats $(0.07) Estimate, Sales $41.378M Miss $41.964M Estimate
Axogen (NASDAQ:AXGN) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.07) by 14.29 percent. This is a 40 percent increase over losses of $(0.10) per shar
AxoGen Updates Corporate Presentation for Stakeholders
Earnings Flash (AXGN) AXOGEN Posts Q1 Revenue $41.4M, Vs. Street Est of $42.1M
07:11 AM EDT, 05/02/2024 (MT Newswires) -- Earnings Flash (AXGN) AXOGEN Posts Q1 Revenue $41.4M, vs. Street Est of $42.1M
Axogen Had Cash, Cash Equivalents, and Investments on March 31 of $23.6M >AXGN
Axogen Had Cash, Cash Equivalents, and Investments on March 31 of $23.6M >AXGN
Axogen Sees 2024 Rev $177M-$181M >AXGN
Axogen Sees 2024 Rev $177M-$181M >AXGN
Axogen 1Q Loss/Shr 15c >AXGN
Axogen 1Q Loss/Shr 15c >AXGN
Axogen, Inc Reports First Quarter 2024 Financial Results
Axogen Announces First Surgical Implants of Avive+ Soft Tissue Matrix
ALACHUA, Fla. and TAMPA, Fla., April 29, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, announces the first
Axogen, Inc. to Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024
ALACHUA, Fla. and TAMPA, Fla., April 16, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced
Investors Give AxoGen, Inc. (NASDAQ:AXGN) Shares A 28% Hiding
The AxoGen, Inc. (NASDAQ:AXGN) share price has softened a substantial 28% over the previous 30 days, handing back much of the gains the stock has made lately.
Director Gregory Freitag Sells 25,000 Shares of Axogen Inc (AXGN)
AxoGen(AXGN.US) Director Sells US$225K in Common Stocks
$AxoGen(AXGN.US)$ Director Freitag Gregory Gene sold 25,000 shares of Common Stocks on Mar 7, 2024 at an average price of $9 for a total value of $225K.Source: Announcement What is statement of change
AxoGen(AXGN.US) Officer Sells US$319.89K in Common Stocks
$AxoGen(AXGN.US)$ Officer Donovan Michael Patrick sold 36,310 shares of Common Stocks on Mar 7, 2024 at an average price of $8.81 for a total value of $319.89K.Source: Announcement What is statement o
Axogen Insider Sold Shares Worth $319,891, According to a Recent SEC Filing
Michael Patrick Donovan, Vice President, Operations, on March 07, 2024, sold 36,310 shares in Axogen (AXGN) for $319,891. Following the Form 4 filing with the SEC, Donovan has control over a total of
US$13.80 - That's What Analysts Think AxoGen, Inc. (NASDAQ:AXGN) Is Worth After These Results
New Accounting & Financial Operations Risk for AxoGen – What's the Latest?
Analysis
Price Target
No Data
